Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;23(9):903-911.
doi: 10.1007/s10151-019-02094-8. Epub 2019 Oct 10.

Long-term oncological results after transanal total mesorectal excision for rectal carcinoma

Jeroen C Hol  1 , Stefan E van Oostendorp  2 , Jurriaan B Tuynman  2 , Colin Sietses  3
Affiliations

Long-term oncological results after transanal total mesorectal excision for rectal carcinoma

Jeroen C Hol et al. Tech Coloproctol. 2019 Sep.

Abstract

Background: Transanal total mesorectal excision (TaTME) for mid and low rectal cancer has been shown to improve short-term outcomes, mostly due to lower conversion rates and with improved quality of the specimen. However, robust long-term oncological data supporting the encouraging clinical and pathological outcomes are lacking.

Methods: All consecutive patients undergoing TaTME with curative intent for mid or low rectal cancer in two referral centers in The Netherlands between January 2012 and April 2016 with a complete and minimum follow-up of 36 months were included. The primary outcome was local recurrence rate. Secondary outcomes were disease-free survival, overall survival and development of metastasis.

Results: There were 159 consecutive patients. Their mean age was 66.9 (10.2) years and 66.7% of all patients were men. Pathological analysis showed a complete mesorectum in 139 patients (87.4%), nearly complete in 16 (10.1%) and an incomplete mesorectum in 4 (2.5%). There was involvement of the CRM (< 1 mm) in one patient (0.6%) and no patients had involvement of the distal margin (< 5 mm). Final postoperative staging after neoadjuvant therapy was stage 0 in 11 patients (6.9%), stage I in 73 (45.9%), stage II in 31 (19.5%), stage III in 37 (23.3%) and stage IV in 7 (4.4%). The 3-year local recurrence rate was 2.0% and the 5-year local recurrence rate was 4.0%. Median time to local recurrence was 19.2 months. Distant metastases were found in 22 (13.8%) patients and were diagnosed after a median of 6.9 months (range 1.1-50.4) months. Disease-free survival was 92% at 3 years and 81% at 5 years. Overall survival was 83.6% at 3 years and 77.3% at 5 years.

Conclusions: The long-term follow-up of the current cohort confirms the oncological safety and feasibility of TaTME in two high volume referral centers for rectal carcinoma. However, further robust and audited data must confirm current findings before widespread implementation of TaTME.

Keywords: Colorectal cancer; Long-term results; Transanal TME.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curve of local recurrence-free survival after TaTME
Fig. 2
Fig. 2
Kaplan–Meier curve of disease-free survival after TaTME
Fig. 3
Fig. 3
Kaplan–Meier curve of overall survival after TaTME
See this image and copyright information in PMC

References

    1. Sylla P, et al. NOTES transanal rectal cancer resection using transanal endoscopic microsurgery and laparoscopic assistance. Surg Endosc. 2010;24(5):1205–1210. doi: 10.1007/s00464-010-0965-6. - DOI - PubMed
    1. Helbach MV, et al. Transanal total mesorectal excision for rectal carcinoma: short-term outcomes and experience after 80 cases. Surg Endosc. 2016;30(2):464–470. doi: 10.1007/s00464-015-4221-y. - DOI - PubMed
    1. Deijen CL, et al. Clinical outcomes and case volume effect of transanal total mesorectal excision for rectal cancer: a systematic review. Tech Coloproctol. 2016;20(12):811–824. doi: 10.1007/s10151-016-1545-0. - DOI - PMC - PubMed
    1. Zhang X, et al. Short- and long-term outcomes of transanal versus laparoscopic total mesorectal excision for mid-to-low rectal cancer: a meta-analysis. Surg Endosc. 2019;33(3):972–985. doi: 10.1007/s00464-018-6527-z. - DOI - PubMed
    1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery–the clue to pelvic recurrence? Br J Surg. 1982;69(10):613–616. doi: 10.1002/bjs.1800691019. - DOI - PubMed

MeSH terms

LinkOut - more resources